ALBRIOZA Commercial Launch
AMX0035 Targets Both Pathways Simultaneously to Prevent or
Slow Cell Death
AMX0035 Effect in Relevant
Preclinical Models
Glutamate excitotoxicity model showing
favorable effects on neuronal survival1
Models of primary mitochondrial disease
showing restoration of mitochondrial
functions1
Protection against neuronal death in model
of primary cortical neuron damage2
AMX0035 demonstrates synergistic protection of
cortical neurons against peroxide-mediated neuronal
death in a range of ratios²
Cell Viability (%) →
60
150
Taurursodiol µM →
900
700
600
500
400
300
200
100
Sodium Phenylbutyrate μM
Figure from Cohen J, et al. Clinical trial design for a phase II, randomized, placebo-controlled trial of AMX0035
in amyotrophic lateral sclerosis (CENTAUR). Poster presented at: 28th International Symposium for ALS/MND;
December 4-10, 2017; Boston, MA.
MOA of AMX0035 in ALS is unknown
1. Data on File. Amylyx Pharmaceuticals. 1. Cohen J, et al. Clinical trial design for a phase II, randomized, placebo-controlled trial of AMX0035 in amyotrophic lateral sclerosis
(CENTAUR). Poster presented at: 28th International Symposium for ALS/MND; December 4-10, 2017; Boston, MA.
AMYLYX 27View entire presentation